Advertisement
HALO vs HMN
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HALO is a StrongBuy and HMN is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
HALO’s FA Score shows that 1 FA rating(s) are green whileHMN’s FA Score has 1 green FA rating(s).
- HALO’s FA Score: 1 green, 4 red.
- HMN’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
HALO’s TA Score shows that 3 TA indicator(s) are bullish while HMN’s TA Score has 3 bullish TA indicator(s).
- HALO’s TA Score: 3 bullish, 3 bearish.
- HMN’s TA Score: 3 bullish, 4 bearish.
Price Growth
HALO (@Biotechnology) experienced а +2.80% price change this week, while HMN (@Property/Casualty Insurance) price change was -0.35% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +6.93%. For the same industry, the average monthly price growth was +17.38%, and the average quarterly price growth was -0.11%.
The average weekly price growth across all stocks in the @Property/Casualty Insurance industry was +0.43%. For the same industry, the average monthly price growth was +0.61%, and the average quarterly price growth was +17.53%.
Reported Earning Dates
HALO is expected to report earnings on Nov 10, 2025.
HMN is expected to report earnings on Oct 30, 2025.
Industries' Descriptions
@Biotechnology (+6.93% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Property/Casualty Insurance (+0.43% weekly)Property and casualty companies insure against accidents of non-physical harm, such as lawsuits, damage to personal assets, car crashes and more. Progressive Corporation, Travelers Companies, Inc. and Allstate Corporation are some of the biggest providers of such products.
| HALO | HMN | HALO / HMN | |
| Capitalization | 6.65B | 1.5B | 445% |
| EBITDA | 705M | N/A | - |
| Gain YTD | 12.947 | 10.407 | 124% |
| P/E Ratio | 14.36 | 33.55 | 43% |
| Revenue | 1.08B | 1.43B | 76% |
| Total Cash | 748M | 552M | 136% |
| Total Debt | 1.51B | 546M | 276% |
HALO | HMN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 75 Overvalued | 30 Undervalued | |
PROFIT vs RISK RATING 1..100 | 40 | 50 | |
SMR RATING 1..100 | 12 | 87 | |
PRICE GROWTH RATING 1..100 | 58 | 51 | |
P/E GROWTH RATING 1..100 | 90 | 83 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
HMN's Valuation (30) in the Multi Line Insurance industry is somewhat better than the same rating for HALO (75) in the Biotechnology industry. This means that HMN’s stock grew somewhat faster than HALO’s over the last 12 months.
HALO's Profit vs Risk Rating (40) in the Biotechnology industry is in the same range as HMN (50) in the Multi Line Insurance industry. This means that HALO’s stock grew similarly to HMN’s over the last 12 months.
HALO's SMR Rating (12) in the Biotechnology industry is significantly better than the same rating for HMN (87) in the Multi Line Insurance industry. This means that HALO’s stock grew significantly faster than HMN’s over the last 12 months.
HMN's Price Growth Rating (51) in the Multi Line Insurance industry is in the same range as HALO (58) in the Biotechnology industry. This means that HMN’s stock grew similarly to HALO’s over the last 12 months.
HMN's P/E Growth Rating (83) in the Multi Line Insurance industry is in the same range as HALO (90) in the Biotechnology industry. This means that HMN’s stock grew similarly to HALO’s over the last 12 months.
| HALO | HMN | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | 4 days ago 74% | 4 days ago 47% |
| Momentum ODDS (%) | 4 days ago 74% | 4 days ago 60% |
| MACD ODDS (%) | 5 days ago 71% | 4 days ago 46% |
| TrendWeek ODDS (%) | 4 days ago 75% | 4 days ago 50% |
| TrendMonth ODDS (%) | 4 days ago 71% | 4 days ago 55% |
| Advances ODDS (%) | 4 days ago 77% | 6 days ago 56% |
| Declines ODDS (%) | 7 days ago 68% | 12 days ago 51% |
| BollingerBands ODDS (%) | N/A | N/A |
| Aroon ODDS (%) | 4 days ago 63% | 4 days ago 54% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| KMVAX | 36.54 | 0.52 | +1.44% |
| Kirr Marbach Partners Value | |||
| VDADX | 56.44 | 0.42 | +0.75% |
| Vanguard Dividend Appreciation Index Adm | |||
| GCMCX | 29.39 | 0.17 | +0.58% |
| Goldman Sachs Mid Cap Value C | |||
| LRSTX | 20.74 | 0.12 | +0.58% |
| Lord Abbett Small Cap Value R5 | |||
| OSMYX | 42.67 | -0.09 | -0.21% |
| Invesco International Small-Mid Com Y | |||
HMN and
Correlation & Price change
A.I.dvisor indicates that over the last year, HMN has been closely correlated with CINF. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if HMN jumps, then CINF could also see price increases.
| Ticker / NAME | Correlation To HMN | 1D Price Change % | ||
|---|---|---|---|---|
| HMN | 100% | +1.62% | ||
| CINF - HMN | 69% Closely correlated | +1.70% | ||
| L - HMN | 67% Closely correlated | +1.15% | ||
| SAFT - HMN | 66% Loosely correlated | +1.52% | ||
| THG - HMN | 64% Loosely correlated | +1.17% | ||
| CNA - HMN | 61% Loosely correlated | +0.53% | ||
More | ||||